Cipher Pharmaceuticals Focuses On Natroba™ Growth And MOB-015 Trial Results

Cipher Pharmaceuticals Inc. shared an update regarding its partner, Moberg Pharma AB, which announced that MOB-015, a treatment for nail fungus, did not achieve the primary endpoint in its North American Phase 3 study. The study results confirm earlier indications previously disclosed by Moberg and announced by Cipher on September 13, 2024.

The Phase 3 trial involved an adjusted dosing schedule: 8 weeks of daily treatment followed by weekly maintenance for 40 weeks instead of daily dosing throughout. However, the primary endpoint, the complete cure of the target toenail at 52 weeks, was not reached. A complete cure requires both a clear nail and a mycological cure. Cipher holds exclusive rights to market MOB-015 in Canada under a licensing agreement with Moberg signed on September 18, 2018. The contract specifies that Cipher has no further financial obligations if specific development and regulatory milestones are met.

The company plans to review the entire trial results once available to determine its next steps for the product. However, this outcome does not impact Cipher’s current sales or earnings. Cipher remains focused on integrating the recently acquired Natroba™ business from ParaPRO LLC, a deal announced on July 29, 2024. The company sees significant growth potential for Natroba™ in the U.S. and international markets. This integration and other growth opportunities remain a top priority for the near term.